A Multicenter Randomized Controlled Trial of Best Available

Recruiting

18-55 years

All

Phase N/A

4 participants needed

1 Location

Brief description of study

The purpose of this study is to compare efficacy and safety of Autologous Hematopoietic Stem Cell Transplant (AHSCT) to best available therapy (BAT) in relapsing MS. Best available therapy is referring to the best available medications that are used to treat MS. Patients who agree to participate in the experimental treatment study will be randomly chosen (like a coin flip) to have an AHSCT or BAT. Neither you nor your doctor are able to decide which treatment you will receive. In addition, patients interested in participating must have permission from their insurance company to enter the trial.

Detailed description of study

card43

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Multiple Sclerosis
Age: Between 18 Years - 55 Years
Gender: All

Updated on 22 Aug 2024. Study ID: 842819

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).